The reinforcing and other behavioral effects of psychomotor stimulants including cocaine and amphetamine involve actions at D1 and D2 brain dopamine receptors. Information about the behavioral effects of agonists and antagonists that act selectively at different subtypes of dopamine receptors is fundamental to understanding the roles of these receptors in the effects of abused drugs. Recent studies have shown that the effects of dopaminergic drugs differ importantly in primate and nonprimate species and that the effects of direct D1 and D2 agonists can be related to the reinforcing and other behavioral effects of psychomotor stimulants in monkeys. We propose to continue our ongoing research in studies involving schedule-controlled performance, drug self-administration, drug discrimination, and unconditioned behavior. In additional studies, we will determine how the effects of full agonists are modified by different types of parallel agonists. The results of these studies will provide fundamental information regarding the pharmacological specificity and quantitative nature of agonist actions at the different types of dopamine receptors and allow us to assess the relative contribution of different dopamine receptor mechanisms in the reinforcing and other behavioral effects of psychomotor stimulants. We also propose to initiate in vivo micro dialysis experiments in conjunction with our-behavioral studies of abuse-related effects of psychomotor stimulants. The combination of these on-line neurochemical sampling techniques and behavioral procedures will enable us to evaluate changes in brain dopamine that are associated with behavior leading to drug self-administration as well as neurochemical effects produced by the self-administered drug. Finally, we will study the effect of chronic administration of D1 and D2 full agonists. Chronic use is a cardinal feature of drug abuse. Our studies to determine how chronic administration alters the effects of dopaminergic agonists differing in receptor selectivity and efficacy will provide information essential for understanding how chronic use of psychomotor stimulants may alter different dopamine brain mechanisms.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
2R01DA003774-11
Application #
2116818
Study Section
Special Emphasis Panel (SRCD (26))
Project Start
1985-08-01
Project End
2000-07-31
Budget Start
1995-08-15
Budget End
1996-07-31
Support Year
11
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Harvard University
Department
Veterinary Sciences
Type
Schools of Medicine
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115
Desai, Rajeev I; Bergman, Jack (2010) Drug discrimination in methamphetamine-trained rats: effects of cholinergic nicotinic compounds. J Pharmacol Exp Ther 335:807-16
Bergman, Jack (2008) Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify). Exp Clin Psychopharmacol 16:475-83
Desai, Rajeev I; Neumeyer, John L; Bergman, Jack et al. (2007) Pharmacological characterization of the effects of dopamine D(1) agonists on eye blinking in rats. Behav Pharmacol 18:745-54
Desai, Rajeev I; Neumeyer, John L; Paronis, Carol A et al. (2007) Behavioral effects of the R-(+)- and S-(-)-enantiomers of the dopamine D(1)-like partial receptor agonist SKF 83959 in monkeys. Eur J Pharmacol 558:98-106
Bergman, Jack; Paronis, Carol A (2006) Measuring the reinforcing strength of abused drugs. Mol Interv 6:273-83
Gasior, Maciej; Bergman, Jack; Kallman, Mary Jeanne et al. (2005) Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys. Neuropsychopharmacology 30:758-64
Jutkiewicz, Emily M; Bergman, Jack (2004) Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions. J Pharmacol Exp Ther 311:1008-15
Gasior, Maciej; Paronis, Carol A; Bergman, Jack (2004) Modification by dopaminergic drugs of choice behavior under concurrent schedules of intravenous saline and food delivery in monkeys. J Pharmacol Exp Ther 308:249-59
Czoty, Paul W; Ramanathan, Chinnasamy R; Mutschler, Nicole H et al. (2004) Drug discrimination in methamphetamine-trained monkeys: effects of monoamine transporter inhibitors. J Pharmacol Exp Ther 311:720-7
Czoty, Paul W; Makriyannis, Alexandros; Bergman, Jack (2004) Methamphetamine discrimination and in vivo microdialysis in squirrel monkeys. Psychopharmacology (Berl) 175:170-8

Showing the most recent 10 out of 52 publications